A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date8/20/20 → 3/31/23

Funding

  • Eli Lilly ( Award # )